TABLE 2. Respiratory virus detections* among enrolled children and adolescents aged <18 years, by highest level of care setting and surveillance season† — New Vaccine Surveillance Network, United States, December 2016–August 2021.
| Characteristic | Viral
pathogen, no. (column %) |
||||||
|---|---|---|---|---|---|---|---|
| Adenovirus |
Influenza |
HMPV |
HPIV1–3 |
RSV |
RV/EV |
SARS-CoV-2§ |
|
| N = 48,859 | N = 49,045 | N = 48,859 | N = 48,859 | N = 49,994 | N = 48,847 | N = 16,386 | |
|
Highest care
setting
| |||||||
| Inpatient |
872 (4.1)
|
1,122 (5.2)
|
930 (4.3)
|
1,081 (5.0)
|
5,085 (23.7)
|
6,551 (30.6)
|
377 (7.1)
|
| ED |
1,622 (7.2)
|
2,451 (10.8)
|
960 (4.2)
|
1,903 (8.4)
|
2,936 (12.9)
|
6,493 (28.6)
|
383 (5.9)
|
| Outpatient¶ |
122 (2.6)
|
75 (1.5)
|
47 (1.0)
|
195 (4.1)
|
440 (7.6)
|
1,862 (39.3)
|
411 (9.0)
|
|
Surveillance
season
| |||||||
| 2016–2017 |
600 (6.0) |
797 (8.0) |
565 (5.7) |
696 (7.0) |
1,803 (18.1) |
2,888 (29.1) |
NA |
| 2017–2018 |
538 (6.3) |
856 (10.1) |
451 (5.3) |
599 (7.0) |
1,512 (17.8) |
2,618 (30.8) |
NA |
| 2018–2019 |
643 (6.8) |
816 (8.6) |
524 (5.5) |
784 (8.2) |
1,859 (17.9) |
3,023 (31.8) |
NA |
| 2019–2020 |
458 (5.1) |
1,169 (12.7) |
368 (4.1) |
166 (1.8) |
1,845 (20.0) |
2,108 (23.4) |
258 (6.8) |
| 2020–2021 |
377 (3.2) |
10 (0.1) |
29 (0.3) |
934 (7.9) |
1,442 (12.1) |
4,269 (35.9) |
913 (7.3) |
| All years | 2,616 (5.4) | 3,648 (7.4) | 1,937 (4.0) | 3,179 (6.5) | 8,461 (16.9) | 14,906 (30.5) | 1,171 (7.1) |
Abbreviations: ED = emergency department; HMPV = human metapneumovirus; HPIV1–3 = human parainfluenza virus types 1–3; NA = not applicable; RSV = respiratory syncytial virus; RV/EV = rhinovirus and enterovirus.
* Respiratory virus detection results are from research swab specimens that underwent molecular testing, except for SARS-CoV-2, which included both research and clinical specimens to most accurately represent viral detections across surveillance years. Denominators for positivity rates are pathogen-specific.
† Surveillance seasons during 2016–2017 were December 1, 2016–November 30, 2017; 2017–2018: December 1, 2017–October 31, 2018; 2018–2019: November 1, 2018–October 31, 2019; 2019–2020: November 1, 2019–September 14, 2020; 2020–2021: September 15, 2020–August 31, 2021.
§ SARS-CoV-2 was first detected in 2020, test results for SARS-CoV-2 reported in this table are from the pandemic period (March 2020–August 2021); surveillance years 2016–2017 through 2018–2019 were not applicable.
¶ Outpatient data were not included for seasons 2016–2017 and 2017–2018 because outpatient enrollment did not begin until November 2018.